Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study

• Main Authors: Annie Delaunois (Author), François‐Xavier Mathy (Author), Miranda Cornet (Author), Vitalina Gryshkova (Author), Chloé Korlowski (Author), François Bonfitto (Author), Juliane Koch (Author), Anne‐Françoise Schlit (Author), Simon Hebeisen (Author), Elisa Passini (Author), Blanca Rodriguez (Author), Jean‐Pierre Valentin (Author)
• Format: Book
• Published: Wiley, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Levetiracetam (LEV), a well‐established anti‐seizure medication (ASM), was launched before the original ICH S7B nonclinical guidance assessing QT prolongation potential and the introduction of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm. No information was available on it...